Investors should consider the board's strong support for John M. Starcher, Jr. despite the ISS and Glass Lewis recommendation against his re-election. The primary consideration is whether Starcher's attendance in 2025, which was due to a single scheduling conflict, outweighs his valuable industry experience and contributions to the company.
Price Chart
Executive Summary
Pediatrix Medical Group is holding its 2026 Annual Meeting of Shareholders on May 7, 2026, to vote on nine director nominees. Institutional Shareholder Services (ISS) and Glass, Lewis & Co. recommend voting against the re-election of John M. Starcher, Jr. due to his attendance falling below 75% in 2025. However, the company's board strongly supports Starcher, citing his valuable healthcare industry experience and leadership.
Key Financial Metrics
Key Facts
- Pediatrix Medical Group is holding its 2026 Annual Meeting of Shareholders on May 7, 2026.
- The board of directors recommends voting 'FOR' all nine director nominees.
- Institutional Shareholder Services (ISS) and Glass, Lewis & Co. recommend voting 'FOR' eight of the nine director nominees.
- ISS and Glass Lewis recommend voting 'AGAINST' the re-election of John M. Starcher, Jr. due to his attendance falling below 75% in 2025.
- The company's board strongly supports Starcher, citing his valuable healthcare industry experience and leadership.
- Starcher attended 73% of combined board and committee meetings in 2025, missing only one board meeting and two committee meetings due to a single unavoidable scheduling conflict.
- The company states that Starcher has attended all board and applicable committee meetings in 2026.
Financial Impact
No direct financial impact from this proxy statement. The vote on director nominees is a governance matter.
Risk Factors
- Potential for shareholder dissent if a significant number of investors follow the ISS and Glass Lewis recommendation and vote against Starcher's re-election.
- Reputational risk if Starcher's attendance issues persist in the future, despite the company's assurance that it will not be an issue going forward.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-161594 |
| Document: 0001193125-26-161594-index-headers.html | 0001193125-26-161594 |
| Document: 0001193125-26-161594-index.html | 0001193125-26-161594 |
| Document: 0001193125-26-161594.txt | 0001193125-26-161594 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 12w ago | 8-K | $24.71 $26.47 | ▲ +7.12% | ▲ +8.36% | $28.84 (+16.71%) |
Jul 24, 2026 13w ago | 8-K | $26.14 $26.60 | ▲ +1.76% | ▼ −1.54% | $28.84 (+10.33%) |
Jul 15, 2026 14w ago | 8-K | $25.88 $26.50 | ▲ +2.40% | ▲ +0.05% | $28.84 (+11.44%) |
Apr 17, 2026 27w ago | DEFA14A | $23.19 $22.64 | ▼ −2.37% | ▼ −6.57% | $28.84 (+24.36%) |
Mar 27, 2026 30w ago | DEFA14A | $20.50 $23.39 | ▲ +14.10% | ▲ +1.36% | $28.84 (+40.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers